DANONE (BSN.DE) Fundamental Analysis & Valuation
FRA:BSN • FR0000120644
Current stock price
67.54 EUR
-0.58 (-0.85%)
Last:
This BSN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BSN.DE Profitability Analysis
1.1 Basic Checks
- BSN had positive earnings in the past year.
- BSN had a positive operating cash flow in the past year.
- BSN had positive earnings in each of the past 5 years.
- In the past 5 years BSN always reported a positive cash flow from operatings.
1.2 Ratios
- With a Return On Assets value of 4.03%, BSN perfoms like the industry average, outperforming 56.45% of the companies in the same industry.
- BSN has a Return On Equity (10.73%) which is comparable to the rest of the industry.
- BSN's Return On Invested Capital of 7.75% is fine compared to the rest of the industry. BSN outperforms 66.13% of its industry peers.
- BSN had an Average Return On Invested Capital over the past 3 years of 7.51%. This is in line with the industry average of 7.10%.
- The last Return On Invested Capital (7.75%) for BSN is above the 3 year average (7.51%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.03% | ||
| ROE | 10.73% | ||
| ROIC | 7.75% |
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
1.3 Margins
- BSN has a Profit Margin of 6.66%. This is in the better half of the industry: BSN outperforms 62.90% of its industry peers.
- In the last couple of years the Profit Margin of BSN has declined.
- BSN has a better Operating Margin (13.43%) than 83.87% of its industry peers.
- BSN's Operating Margin has been stable in the last couple of years.
- BSN has a Gross Margin of 50.62%. This is amongst the best in the industry. BSN outperforms 80.65% of its industry peers.
- In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.43% | ||
| PM (TTM) | 6.66% | ||
| GM | 50.62% |
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
2. BSN.DE Health Analysis
2.1 Basic Checks
- BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- BSN has less shares outstanding than it did 1 year ago.
- BSN has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, BSN has a worse debt to assets ratio.
2.2 Solvency
- BSN has an Altman-Z score of 2.37. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
- BSN has a Altman-Z score of 2.37. This is in the better half of the industry: BSN outperforms 62.90% of its industry peers.
- The Debt to FCF ratio of BSN is 5.29, which is a neutral value as it means it would take BSN, 5.29 years of fcf income to pay off all of its debts.
- BSN's Debt to FCF ratio of 5.29 is fine compared to the rest of the industry. BSN outperforms 67.74% of its industry peers.
- A Debt/Equity ratio of 0.73 indicates that BSN is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.73, BSN is doing worse than 61.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | 5.29 | ||
| Altman-Z | 2.37 |
ROIC/WACC1.22
WACC6.33%
2.3 Liquidity
- BSN has a Current Ratio of 0.90. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Current ratio value of 0.90, BSN is not doing good in the industry: 77.42% of the companies in the same industry are doing better.
- BSN has a Quick Ratio of 0.90. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
- BSN's Quick ratio of 0.75 is in line compared to the rest of the industry. BSN outperforms 40.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.75 |
3. BSN.DE Growth Analysis
3.1 Past
- BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.68%.
- BSN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.61% yearly.
- The Revenue has decreased by -0.34% in the past year.
- Measured over the past years, BSN shows a small growth in Revenue. The Revenue has been growing by 2.93% on average per year.
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%
3.2 Future
- Based on estimates for the next years, BSN will show a small growth in Earnings Per Share. The EPS will grow by 7.81% on average per year.
- The Revenue is expected to grow by 4.25% on average over the next years.
EPS Next Y6.56%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
EPS Next 5Y7.81%
Revenue Next Year2.65%
Revenue Next 2Y3.35%
Revenue Next 3Y3.59%
Revenue Next 5Y4.25%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. BSN.DE Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 17.77, which indicates a rather expensive current valuation of BSN.
- BSN's Price/Earnings ratio is in line with the industry average.
- When comparing the Price/Earnings ratio of BSN to the average of the S&P500 Index (27.42), we can say BSN is valued slightly cheaper.
- The Price/Forward Earnings ratio is 16.68, which indicates a correct valuation of BSN.
- BSN's Price/Forward Earnings ratio is in line with the industry average.
- BSN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.24.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.77 | ||
| Fwd PE | 16.68 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as BSN.
- 67.74% of the companies in the same industry are more expensive than BSN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.89 | ||
| EV/EBITDA | 9.38 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSN does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of BSN may justify a higher PE ratio.
PEG (NY)2.71
PEG (5Y)6.8
EPS Next 2Y6.99%
EPS Next 3Y7.19%
5. BSN.DE Dividend Analysis
5.1 Amount
- BSN has a Yearly Dividend Yield of 3.33%.
- Compared to an average industry Dividend Yield of 2.37, BSN pays a bit more dividend than its industry peers.
- BSN's Dividend Yield is rather good when compared to the S&P500 average which is at 1.81.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.33% |
5.2 History
- The dividend of BSN has a limited annual growth rate of 0.46%.
Dividend Growth(5Y)0.46%
Div Incr Years4
Div Non Decr Years5
5.3 Sustainability
- BSN pays out 75.94% of its income as dividend. This is not a sustainable payout ratio.
- The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP75.94%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
BSN.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:BSN (4/24/2026, 7:00:00 PM)
67.54
-0.58 (-0.85%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)02-20 2026-02-20/bmo
Earnings (Next)04-22 2026-04-22/bmo
Inst Owners55.19%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap46.02B
Revenue(TTM)27.28B
Net Income(TTM)1.82B
Analysts75.76
Price Target81.39 (20.51%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.33% |
Yearly Dividend2.15
Dividend Growth(5Y)0.46%
DP75.94%
Div Incr Years4
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.76%
PT rev (3m)0.37%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.89%
EPS NY rev (3m)-3.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-0.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.77 | ||
| Fwd PE | 16.68 | ||
| P/S | 1.69 | ||
| P/FCF | 16.89 | ||
| P/OCF | 12.17 | ||
| P/B | 2.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.38 |
EPS(TTM)3.8
EY5.63%
EPS(NY)4.05
Fwd EY6%
FCF(TTM)4
FCFY5.92%
OCF(TTM)5.55
OCFY8.21%
SpS40.04
BVpS24.83
TBVpS-9.13
PEG (NY)2.71
PEG (5Y)6.8
Graham Number46.0744 (-31.78%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.03% | ||
| ROE | 10.73% | ||
| ROCE | 12.04% | ||
| ROIC | 7.75% | ||
| ROICexc | 9.68% | ||
| ROICexgc | 76.66% | ||
| OM | 13.43% | ||
| PM (TTM) | 6.66% | ||
| GM | 50.62% | ||
| FCFM | 9.99% |
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
ROICexc(3y)9.24%
ROICexc(5y)8.74%
ROICexgc(3y)70.2%
ROICexgc(5y)59.95%
ROCE(3y)11.59%
ROCE(5y)10.94%
ROICexgc growth 3Y20.15%
ROICexgc growth 5Y16.9%
ROICexc growth 3Y6.6%
ROICexc growth 5Y4.3%
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
F-Score7
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | 5.29 | ||
| Debt/EBITDA | 2.46 | ||
| Cap/Depr | 77.86% | ||
| Cap/Sales | 3.87% | ||
| Interest Coverage | 21.06 | ||
| Cash Conversion | 75.3% | ||
| Profit Quality | 150.06% | ||
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | 2.37 |
F-Score7
WACC6.33%
ROIC/WACC1.22
Cap/Depr(3y)69.82%
Cap/Depr(5y)67.75%
Cap/Sales(3y)3.44%
Cap/Sales(5y)3.55%
Profit Quality(3y)197.16%
Profit Quality(5y)188.14%
High Growth Momentum
Growth
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
EPS Next Y6.56%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
EPS Next 5Y7.81%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%
Revenue Next Year2.65%
Revenue Next 2Y3.35%
Revenue Next 3Y3.59%
Revenue Next 5Y4.25%
EBIT growth 1Y3.01%
EBIT growth 3Y2.73%
EBIT growth 5Y1.96%
EBIT Next Year36.46%
EBIT Next 3Y14.84%
EBIT Next 5Y11.54%
FCF growth 1Y-6.26%
FCF growth 3Y9.25%
FCF growth 5Y6.33%
OCF growth 1Y-1.31%
OCF growth 3Y8.46%
OCF growth 5Y4.96%
DANONE / BSN.DE Fundamental Analysis FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.
What is the valuation status for BSN stock?
ChartMill assigns a valuation rating of 4 / 10 to DANONE (BSN.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for DANONE?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What is the financial health of DANONE (BSN.DE) stock?
The financial health rating of DANONE (BSN.DE) is 4 / 10.
Can you provide the dividend sustainability for BSN stock?
The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 75.94%.